Literature DB >> 8959371

Circadian rhythms and cancer chemotherapy.

P A Wood1, W J Hrushesky.   

Abstract

Temporal coordination of biologic processes with an approximately 24-h cycle (circadian) is common throughout the animal and plant kingdom and even in some prokaryotic organisms. In all organisms studied, the capability to keep biologic time is an inherited characteristic located intracellularly. These biological clocks anticipate and get the organism ready for regular environmental changes. This indicates both the ubiquity and the weight of the selective environmental pressure to keep time accurately. Several molecular strategies for biologic time keeping have apparently arisen independently several times throughout evolution. The anatomic, biochemical, and molecular mechanisms of the clock are in the process of being defined. This temporal organization at the cellular, organ, and organismic levels results in predictable differences in the capacity of plants, animals, and human beings to respond to therapeutic interventions administered at different times throughout important biologic cycles (e.g., circadian timed therapy). In the treatment of the cancer bearing host, circadian timing of surgery, anticancer drugs, radiation therapy, and biologic agents can result in improved toxicity profiles, enhanced tumor control, and improved host survival. The routine clinical application of such principles is facilitated by the availability of programmable drug delivery devices. Rhythm frequency ranges other than 24-h (e.g., low frequency: menstrual; high frequency: 10 to 120 min) may also be important to understanding health and disease and to designing successful therapy in diseases as diverse as cancer, infertility, and diabetes.

Entities:  

Mesh:

Year:  1996        PMID: 8959371     DOI: 10.1615/critreveukargeneexpr.v6.i4.10

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  5 in total

Review 1.  The relationship between fatigue and sleep in cancer patients: a review.

Authors:  S Ancoli-Israel; P J Moore; V Jones
Journal:  Eur J Cancer Care (Engl)       Date:  2001-12       Impact factor: 2.520

Review 2.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.

Authors:  Brittney Jung-Hynes; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-01       Impact factor: 13.007

Review 3.  Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.

Authors:  David E Blask; Robert T Dauchy; Leonard A Sauer
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

4.  Sleep dysfunction in patients with cancer.

Authors:  Lavinia Fiorentino; Sonia Ancoli-Israel
Journal:  Curr Treat Options Neurol       Date:  2007-09       Impact factor: 3.598

5.  Modeling biological rhythms in failure time data.

Authors:  Naser B Elkum; James D Myles
Journal:  J Circadian Rhythms       Date:  2006-11-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.